ClinicalTrials.gg
TerminatedNCT00924781Updated Nov 2, 2015Results posted

A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)

A Phase 2 interventional study of MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline and MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline in Anemia and Chronic Kidney Disease, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-11-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.

Enrollment
82nd of 112
39 · median 71
Started
2009
with 2 others
Phase 2
44 of 126
none open now
Registered
105th of 126
by date

Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 82nd largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2009, is one of 44 in phase 2, and was the 105th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing Epoetin Alfa in Anemia, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of intravenous MK2578, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving erythropoietin stimulating agents.

Read the detailed description

This study consists of a 12-week base study (MK2578-003-AM03) and an optional 40-week extension study (MK2578-003-EXT12). Participants who complete 12 weeks of treatment in the base study will enter the extension on the most recent dose administered in the base study or a newly adjusted dose, if adjustment is required to bring Hg levels within range. Participants' doses of MK2578 will be adjusted upward or downward during the extension study to maintain Hb in the range of 10-12 g/dL.

03

Conditions studied

  • Anemia
  • Chronic Kidney Disease

Keywords

  • Anemia associated with chronic kidney disease (CKD)
  • Hemodialysis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Base Study:

  • Patient is male or is a female who either cannot have children or who agrees to use appropriate measures
  • Patient has been on hemodialysis for at least 6 months when is signed
  • Patient has received intravenous epoetin alfa or epoetin beta for a least 6 months when the informed consent is signed

Extension Study:

  • Patient completed the base study through Week 12
  • Patient tolerated MK2578 and demonstrated compliance with study procedures

Exclusion criteria

Exclusion Criteria:

  • Patient has a of less than 6 months
  • Patient is scheduled for a kidney transplant within the next 6 months
  • Patient has had a blood transfusion within 12 weeks of screening
  • Patient has had major surgery within 12 weeks of screening or plans to have surgery
  • Patient has (HIV)
  • Patient has history of blood dyscrasia, hematologic disorders or any other disease known to cause anemia
  • Patient has severe congestive heart failure (CHF)
  • Patient has a history of malignant cancer, except certain skin or cervical cancers
  • Patient has a history of grand mal seizures within the last 6 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    MK2578 1 mcg for every 600 U of Epogen at Baseline

    Participants were randomized to receive treatment every week (QW).

    Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline

  • Experimental
    1 mcg of MK2578 for every 600 U of Epogen at Baseline

    Participants were randomized to receive treatment QM.

    Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline

  • Experimental
    MK2578 1 mcg for every 350 U of Epogen at Baseline

    Participants were randomized to receive treatment QW.

    Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline

  • Experimental
    1 mcg of MK2578 for every 350 U of Epogen at Baseline

    Participants were randomized to receive treatment QM.

    Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline

  • Experimental
    MK2578 1 mcg for every 200 U of Epogen at Baseline

    Participants were randomized to receive treatment QW.

    Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline

  • Experimental
    1 mcg of MK2578 for every 200 U of Epogen at Baseline

    Participants were randomized to receive treatment QM.

    Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin (Hg) Level at Week 4

    Time frame: 4 weeks

  2. Number of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)

    Time frame: 12 weeks

  3. Number of Participants With Composite Events of Transfusion-Related Adverse Experiences

    Time frame: 12 weeks

  4. Number of Participants With Composite Events of Infusion Reactions

    Time frame: 12 weeks

  5. Number of Participants With Events of Death, MI, CVA, Peripheral Vascular Thromboses, Vascular Access Thrombosis, Congestive Heart Failure (CHF), Hypertension, Seizure, or Pure Red Cell Aplasia

    Time frame: 12 weeks

  6. Number of Participants With Confirmed, Treatment Emergent Antibodies to MK2578

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in Hg Level at Week 12

    Time frame: 12 weeks

07

Results

Posted Mar 29, 2012
Limitations and caveats
Cohort 3 (MK2578 1mcg/200U) was not initiated because the study was prematurely terminated by the sponsor. All randomized participants received at least one dose of study medication. Data presented are for Cohort 1 and Cohort 2, where applicable.

Participant flow

Participants were recruited from 46 centers (9 centers in Bulgaria, 27 in United States, 3 in Romania, 4 in Italy, and 3 in Poland).

Participant flow — Overall Study
MilestoneMK2578 1mcg/600 U or 1 mcg/350 U QWMK2578 1mcg/600 U or 1 mg/350 U QM
Started2019
Completed89
Not completed1210
Withdrew: Study terminated by sponsor1210

Outcome measures

PrimaryChange From Baseline in Hemoglobin (Hg) Level at Week 4
Time frame:
4 weeks
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin (Hg) Level at Week 4
g/dLMK2578 1mcg/600U QWMK2578 1mcg/600U QMMK2578 1mcg/350U QWMK2578 1mcg/350U QM
Change From Baseline in Hemoglobin (Hg) Level at Week 4-0.6 ± 0.8-0.7 ± 1.0-1.0 ± NA-1.0 ± NA
PrimaryNumber of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)
Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)
ParticipantsMK2578 1mcg/600U QWMK2578 1mcg/600U QMMK2578 1mcg/350U QWMK2578 1mcg/350U QM
Number of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)0100
PrimaryNumber of Participants With Composite Events of Transfusion-Related Adverse Experiences
Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Composite Events of Transfusion-Related Adverse Experiences
ParticipantsMK2578 1mcg/600U QWMK2578 1mcg/600U QMMK2578 1mcg/350U QWMK2578 1mcg/350U QM
Number of Participants With Composite Events of Transfusion-Related Adverse Experiences0000
PrimaryNumber of Participants With Composite Events of Infusion Reactions
Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Composite Events of Infusion Reactions
ParticipantsMK2578 1mcg/600U QWMK2578 1mcg/600 QMMK2578 1mcg/350U QWMK2578 1mcg/350U QM
Number of Participants With Composite Events of Infusion Reactions0000
PrimaryNumber of Participants With Events of Death, MI, CVA, Peripheral Vascular Thromboses, Vascular Access Thrombosis, Congestive Heart Failure (CHF), Hypertension, Seizure, or Pure Red Cell Aplasia
Time frame:
12 weeks
Reported as:
Number · Participants
Number of Participants With Events of Death, MI, CVA, Peripheral Vascular Thromboses, Vascular Access Thrombosis, Congestive Heart Failure (CHF), Hypertension, Seizure, or Pure Red Cell Aplasia
ParticipantsMK2578 1mcg/600U QWMK2578 1mcg/600U QMMK2578 1mcg/350U QWMK2578 1mcg/350U QM
Death0000
MI0100
CVA0000
Peripheral vascular thromboses0000
Vascular access thrombosis0010
CHF0000
Hypertension1100
Seizure0000
Pure red cell aplasia0000
PrimaryNumber of Participants With Confirmed, Treatment Emergent Antibodies to MK2578
Time frame:
12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Hg Level at Week 12
Time frame:
12 weeks
Reported as:
Mean · g/dL
Change From Baseline in Hg Level at Week 12
g/dLMK2578 1mcg/600U QWMK2578 1mcg/600U QMMK2578 1mcg/350U QWMK-2578 1mcg/350U QM
Change From Baseline in Hg Level at Week 12-0.1 ± 1.4-0.5 ± 1.4——

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK2578 QW—1/20 (5%)9/20 (45%)
MK2578 QM—2/19 (10.5%)7/19 (36.8%)
Most frequent serious events
Most frequent serious events
EventMK2578 QWMK2578 QM
Acute mycoardial infarctionCardiac disorders0/201/19
Complications of transplanted kidneyInjury, poisoning and procedural complications0/201/19
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/201/19
Pleural effusionRespiratory, thoracic and mediastinal disorders1/200/19
Most frequent other events
Showing 10 of 45
Most frequent other events
EventMK2578 QWMK2578 QM
Acute myocardial infarctionCardiac disorders0/201/19
Adrenal cystEndocrine disorders0/201/19
Abdominal distentionGastrointestinal disorders0/201/19
GastritisGastrointestinal disorders0/201/19
NauseaGastrointestinal disorders0/201/19
OesophagitisGastrointestinal disorders0/201/19
AstheniaGeneral disorders0/201/19
Non-cardiac chest painGeneral disorders0/201/19
Oedema peripheralGeneral disorders0/201/19
Bacterial disease carrierInfections and infestations0/201/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)MK2578 1mcg/600U QWMK2578 1mcg/600U QMMK2578 1mcg/350U QWMK2578 1mcg/350U QMTotal
Mean46.3 ± 14.2951.7 ± 10.2258.0 ± 8.9160.5 ± 4.5151.0 ± 12.30
Sex: Female, Male
Sex: Female, Male(Participants)MK2578 1mcg/600U QWMK2578 1mcg/600U QMMK2578 1mcg/350U QWMK2578 1mcg/350U QMTotal
Female1083324
Male671115
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Apr 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2009
First posted
Jun 19, 2009
Start
Jun 2009
Primary completionActual
Apr 2010
CompletionActual
May 2010
Results first posted
Mar 29, 2012
Last update
Nov 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00924781
Responsible party
Sponsor
First posted
Jun 19, 2009
Start date
Jun 2009
Primary completion
Apr 2010
Completion
May 2010
Results posted
Mar 29, 2012
Last update
Nov 2, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion